Open-Label Study of Perhexiline in Patients With Hypertrophic Cardiomyopathy and Moderate to Severe Heart Failure

Stopped early · Phase 2

Conditions studied: Cardiomyopathy, Hypertrophic, Cardiomyopathy, Hypertrophic, Familial

In brief

The purpose of this study is to evaluate the effect of perhexiline on exercise performance (efficacy) and safety in patients with hypertrophic cardiomyopathy and moderate-to-severe heart failure following dosing for 16 weeks.

Key facts

Study ID

NCT02862600

Run by

Heart Metabolics Limited

People needed

35

Starts

2016-08-01

Expected to finish

2017-05-22

Last updated by the study team

2017-08-31

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Study site — Stanford, California, United States
• Study site — Indianapolis, Indiana, United States
• Johns Hopkins — Baltimore, Maryland, United States
• University of Maryland — Baltimore, Maryland, United States
• Study site — Detroit, Michigan, United States
• Study site — Columbus, Ohio, United States
• Study site — Portland, Oregon, United States
• Study site — Hershey, Pennsylvania, United States
• Study site — Germantown, Tennessee, United States
• Study site — Salt Lake City, Utah, United States
• Study site — Madison, Wisconsin, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.